vs
EXACT SCIENCES CORP（EXAS）与OUTFRONT Media Inc.（OUT）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是OUTFRONT Media Inc.的1.7倍（$878.4M vs $513.3M），OUTFRONT Media Inc.净利率更高（18.9% vs -9.8%，领先28.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs 4.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $93.3M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 12.1%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
OUTFRONT Media Inc.是一家美国广告企业，业务覆盖美国本土，由首席执行官Nick Brien领导美洲区业务，核心经营广告牌及公共交通展示广告两大业务板块，是户外广告领域的重要参与者。
EXAS vs OUT — 直观对比
营收规模更大
EXAS
是对方的1.7倍
$513.3M
营收增速更快
EXAS
高出19.0%
4.1%
净利率更高
OUT
高出28.6%
-9.8%
自由现金流更多
EXAS
多$27.1M
$93.3M
两年增速更快
EXAS
近两年复合增速
12.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $513.3M |
| 净利润 | $-86.0M | $96.8M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 26.0% |
| 净利率 | -9.8% | 18.9% |
| 营收同比 | 23.1% | 4.1% |
| 净利润同比 | 90.1% | 30.8% |
| 每股收益（稀释后） | $-0.45 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASOUT
| Q4 25 | $878.4M | $513.3M | ||
| Q3 25 | $850.7M | $467.5M | ||
| Q2 25 | $811.1M | $460.2M | ||
| Q1 25 | $706.8M | $390.7M | ||
| Q4 24 | $713.4M | $493.2M | ||
| Q3 24 | $708.7M | $451.9M | ||
| Q2 24 | $699.3M | $477.3M | ||
| Q1 24 | $637.5M | $408.5M |
净利润EXASOUT
| Q4 25 | $-86.0M | $96.8M | ||
| Q3 25 | $-19.6M | $51.3M | ||
| Q2 25 | $-1.2M | $19.5M | ||
| Q1 25 | $-101.2M | $-20.6M | ||
| Q4 24 | $-864.6M | $74.0M | ||
| Q3 24 | $-38.2M | $34.6M | ||
| Q2 24 | $-15.8M | $176.8M | ||
| Q1 24 | $-110.2M | $-27.2M |
毛利率EXASOUT
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASOUT
| Q4 25 | -9.4% | 26.0% | ||
| Q3 25 | -3.0% | 19.2% | ||
| Q2 25 | -0.3% | 12.2% | ||
| Q1 25 | -13.6% | 3.6% | ||
| Q4 24 | -122.8% | 22.5% | ||
| Q3 24 | -5.6% | 15.8% | ||
| Q2 24 | -3.8% | 48.0% | ||
| Q1 24 | -16.7% | 3.4% |
净利率EXASOUT
| Q4 25 | -9.8% | 18.9% | ||
| Q3 25 | -2.3% | 11.0% | ||
| Q2 25 | -0.1% | 4.2% | ||
| Q1 25 | -14.3% | -5.3% | ||
| Q4 24 | -121.2% | 15.0% | ||
| Q3 24 | -5.4% | 7.7% | ||
| Q2 24 | -2.3% | 37.0% | ||
| Q1 24 | -17.3% | -6.7% |
每股收益（稀释后）EXASOUT
| Q4 25 | $-0.45 | $0.57 | ||
| Q3 25 | $-0.10 | $0.29 | ||
| Q2 25 | $-0.01 | $0.10 | ||
| Q1 25 | $-0.54 | $-0.14 | ||
| Q4 24 | $-4.69 | $0.49 | ||
| Q3 24 | $-0.21 | $0.19 | ||
| Q2 24 | $-0.09 | $1.01 | ||
| Q1 24 | $-0.60 | $-0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $99.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $710.4M |
| 总资产 | $5.9B | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASOUT
| Q4 25 | $964.7M | $99.9M | ||
| Q3 25 | $1.0B | $63.0M | ||
| Q2 25 | $858.4M | $28.5M | ||
| Q1 25 | $786.2M | $30.5M | ||
| Q4 24 | $1.0B | $46.9M | ||
| Q3 24 | $1.0B | $28.0M | ||
| Q2 24 | $946.8M | $49.6M | ||
| Q1 24 | $652.1M | $42.4M |
股东权益EXASOUT
| Q4 25 | $2.4B | $710.4M | ||
| Q3 25 | $2.5B | $542.6M | ||
| Q2 25 | $2.5B | $539.1M | ||
| Q1 25 | $2.4B | $566.9M | ||
| Q4 24 | $2.4B | $649.0M | ||
| Q3 24 | $3.2B | $618.2M | ||
| Q2 24 | $3.2B | $664.9M | ||
| Q1 24 | $3.1B | $524.2M |
总资产EXASOUT
| Q4 25 | $5.9B | $5.3B | ||
| Q3 25 | $5.9B | $5.2B | ||
| Q2 25 | $5.8B | $5.1B | ||
| Q1 25 | $5.7B | $5.1B | ||
| Q4 24 | $5.9B | $5.2B | ||
| Q3 24 | $6.7B | $5.2B | ||
| Q2 24 | $6.7B | $5.3B | ||
| Q1 24 | $6.4B | $5.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $118.1M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $93.3M |
| 自由现金流率自由现金流/营收 | 13.7% | 18.2% |
| 资本支出强度资本支出/营收 | 3.6% | 4.8% |
| 现金转化率经营现金流/净利润 | — | 1.22× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $218.8M |
8季度趋势，按日历期对齐
经营现金流EXASOUT
| Q4 25 | $151.7M | $118.1M | ||
| Q3 25 | $219.9M | $88.8M | ||
| Q2 25 | $89.0M | $67.1M | ||
| Q1 25 | $30.8M | $33.6M | ||
| Q4 24 | $47.1M | $124.5M | ||
| Q3 24 | $138.7M | $73.1M | ||
| Q2 24 | $107.1M | $71.0M | ||
| Q1 24 | $-82.3M | $30.6M |
自由现金流EXASOUT
| Q4 25 | $120.4M | $93.3M | ||
| Q3 25 | $190.0M | $67.7M | ||
| Q2 25 | $46.7M | $41.4M | ||
| Q1 25 | $-365.0K | $16.4M | ||
| Q4 24 | $10.7M | $106.3M | ||
| Q3 24 | $112.6M | $55.5M | ||
| Q2 24 | $71.2M | $47.1M | ||
| Q1 24 | $-120.0M | $12.2M |
自由现金流率EXASOUT
| Q4 25 | 13.7% | 18.2% | ||
| Q3 25 | 22.3% | 14.5% | ||
| Q2 25 | 5.8% | 9.0% | ||
| Q1 25 | -0.1% | 4.2% | ||
| Q4 24 | 1.5% | 21.6% | ||
| Q3 24 | 15.9% | 12.3% | ||
| Q2 24 | 10.2% | 9.9% | ||
| Q1 24 | -18.8% | 3.0% |
资本支出强度EXASOUT
| Q4 25 | 3.6% | 4.8% | ||
| Q3 25 | 3.5% | 4.5% | ||
| Q2 25 | 5.2% | 5.6% | ||
| Q1 25 | 4.4% | 4.4% | ||
| Q4 24 | 5.1% | 3.7% | ||
| Q3 24 | 3.7% | 3.9% | ||
| Q2 24 | 5.1% | 5.0% | ||
| Q1 24 | 5.9% | 4.5% |
现金转化率EXASOUT
| Q4 25 | — | 1.22× | ||
| Q3 25 | — | 1.73× | ||
| Q2 25 | — | 3.44× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.68× | ||
| Q3 24 | — | 2.11× | ||
| Q2 24 | — | 0.40× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
OUT
| Static Displays | $236.3M | 46% |
| Other | $134.8M | 26% |
| Digital Displays | $125.3M | 24% |
| Other Revenues | $1.9M | 0% |
